Evidence map›Paper›PMID 34784976›Full record

ArticleGenome medicine2021

Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units.

Themoula Charalampous, Adela Alcolea-Medina, Luke B Snell, Tom G S Williams, Rahul Batra, Christopher Alder, Andrea Telatin, Luigi Camporota, Christopher I S Meadows, Duncan Wyncoll and 12 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06181669 completednot on this mapstarted 2024, after this paper: background citation

Pneumonia Direct Pilot

TypeobservationalSponsorDuke UniversityRan2024 to 2025Enrolled173ConditionsPneumonia, Bacterial, Ventilator Associated PneumoniaArmsPathogen and Host Directed testing
NCT06566898 recruitingnot on this mapstarted 2024, after this paper: background citation

Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study

TypeobservationalSponsorShanghai General Hospital, ChinaRan2024 to 2026Enrolled800ConditionsPneumonia, Next-generation Sequencing, Microbiome, Antimicrobial Resistance
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Article
  3. Microbiome Profiling Reveals Prognostic Heterogeneity inmedRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Routine Metagenomics Service for ICU Patients with Respiratory Infection.American journal of respiratory and critical care medicine · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Themoula Charalampous *Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, Kings College London, London, UK.ORCID 0000-0002-8914-5868
Adela Alcolea-Medina *Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, Kings College London, London, UK.
Luke B Snell *Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, Kings College London, London, UK.
Tom G S WilliamsDepartment of Infectious Diseases, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Rahul BatraCentre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, Kings College London, London, UK.
Christopher AlderCentre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, Kings College London, London, UK.
Andrea TelatinQuadram Institute Bioscience, Norwich Research Park, Norwich, UK.
Luigi CamporotaCritical Care Directorate, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Christopher I S MeadowsCritical Care Directorate, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Duncan WyncollCritical Care Directorate, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Nicholas A BarrettCritical Care Directorate, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Carolyn J HemsleyDepartment of Infectious Diseases, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Lisa BryanInfection Sciences, Viapath, St Thomas' Hospital, London, UK.
William NewsholmeDepartment of Infectious Diseases, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Sara E BoydDepartment of Infectious Diseases, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Anna GreenDepartment of Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Ula MahadevaDepartment of Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Amita PatelCentre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, Kings College London, London, UK.
Penelope R CliffInfection Sciences, Viapath, St Thomas' Hospital, London, UK.
Andrew J PageQuadram Institute Bioscience, Norwich Research Park, Norwich, UK.
Justin O'GradyQuadram Institute Bioscience, Norwich Research Park, Norwich, UK. justin.ogrady@uea.ac.uk.
Jonathan D EdgeworthCentre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, Kings College London, London, UK. jonathan.edgeworth@gstt.nhs.uk.
St Thomas' Hospital · GBNorwich Research Park · GBGuy's and St Thomas' NHS Foundation Trust · GBKing's College London · GB

Funding

Biotechnology and Biological Sciences Research Council BB/CCG1860/1Biotechnology and Biological Sciences Research Council BB/R012504/1, BBS/E/F/000PR10348, BBS/E/F/000PR10349, BBS/E/F/000PR10351, BBS/E/F/000PR10352Medical Research Council MR/N025989/1
6 · The paper itself

Abstract

backgroundClinical metagenomics (CMg) has the potential to be translated from a research tool into routine service to improve antimicrobial treatment and infection control decisions. The SARS-CoV-2 pandemic provides added impetus to realise these benefits, given the increased risk of secondary infection and nosocomial transmission of multi-drug-resistant (MDR) pathogens linked with the expansion of critical care capacity.

methodsCMg using nanopore sequencing was evaluated in a proof-of-concept study on 43 respiratory samples from 34 intubated patients across seven intensive care units (ICUs) over a 9-week period during the first COVID-19 pandemic wave.

resultsAn 8-h CMg workflow was 92% sensitive (95% CI, 75-99%) and 82% specific (95% CI, 57-96%) for bacterial identification based on culture-positive and culture-negative samples, respectively. CMg sequencing reported the presence or absence of β-lactam-resistant genes carried by Enterobacterales that would modify the initial guideline-recommended antibiotics in every case. CMg was also 100% concordant with quantitative PCR for detecting Aspergillus fumigatus from 4 positive and 39 negative samples. Molecular typing using 24-h sequencing data identified an MDR-K. pneumoniae ST307 outbreak involving 4 patients and an MDR-C. striatum outbreak involving 14 patients across three ICUs.

conclusionCMg testing provides accurate pathogen detection and antibiotic resistance prediction in a same-day laboratory workflow, with assembled genomes available the next day for genomic surveillance. The provision of this technology in a service setting could fundamentally change the multi-disciplinary team approach to managing ICU infections. The potential to improve the initial targeted treatment and rapidly detect unsuspected outbreaks of MDR-pathogens justifies further expedited clinical assessment of CMg.

Indexed as

MetagenomicsAnti-Bacterial Agentsbeta-LactamasesCoinfectionCorynebacteriumCOVID-19Cross InfectionDNA, BacterialDrug Resistance, Multiple, BacterialFemaleHumansIntensive Care UnitsKlebsiella pneumoniaeMaleMiddle AgedPolymorphism, Single NucleotideAnti-Bacterial Agentsbeta-LactamasesDNA, Bacterial

Identifiers

PMID34784976
PMCPMC8594956
OpenAlexW3212458738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.